PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat infections in chronic and acute wounds, announced today that it received notice from The NASDAQ Stock Market indicating that its stockholders’ equity at September 30, 2008 was less than the $10 million in stockholders’ equity required for continued listing on The NASDAQ Global Market under Marketplace Rule 4450(a)(3). The notice, which was received in a letter dated November 19, 2008, is a standard communication when a company’s stockholders’ equity is less than the $10 million minimum requirement. The notice has no immediate effect on the listing of the company’s common stock.
